Media stories about AcelRx Pharmaceuticals (NASDAQ:ACRX) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AcelRx Pharmaceuticals earned a news sentiment score of 0.08 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 45.775134811849 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news stories that may have effected Accern Sentiment’s analysis:
AcelRx Pharmaceuticals stock remained flat at $$2.20 during mid-day trading on Monday. The company had a trading volume of 8,108 shares, compared to its average volume of 433,737. The company has a market capitalization of $111.98, a price-to-earnings ratio of -2.00 and a beta of 2.41. AcelRx Pharmaceuticals has a 1-year low of $1.55 and a 1-year high of $5.75. The company has a quick ratio of 4.57, a current ratio of 4.64 and a debt-to-equity ratio of -0.31.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings results on Thursday, March 8th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.20). The business had revenue of $0.74 million for the quarter, compared to the consensus estimate of $2.90 million. research analysts anticipate that AcelRx Pharmaceuticals will post -0.98 EPS for the current fiscal year.
Separately, Zacks Investment Research upgraded AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a report on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $4.92.
COPYRIGHT VIOLATION WARNING: “AcelRx Pharmaceuticals (ACRX) Receiving Somewhat Favorable News Coverage, Report Finds” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/04/09/acelrx-pharmaceuticals-acrx-receiving-somewhat-favorable-news-coverage-report-finds.html.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.